The long-term survival in a group of 370 patients treated for Hodgkin's disease in the years 1971-1996 was retrospectively analyzed. Up to now 191 patients live. 179 patients have died. Since the year 1978 the uniform diagnostic and therapy protocol has been used. The therapy consisted in the combination of a radiation therapy (usual dose 40 Gy) with the COPP chemotherapy (6 cycles). Since the year 1988 the alternation of the ABVD and COPP chemotherapy has been used. According to the stage of the Hodgkin's disease and the patient's age the modification of the therapy was introduced. One chemotherapy cycle was removed for each 10 years above the 50 year age of the patient. The radiation therapy was not applied to the areas of the reproductive organs in young patients to preserve their fertility. The percentage of surviving patients for thirty years was 58.8% for Stage I and IIA,B and for Stage IIIA was 60.72%. In the group of surviving patients, we have registered 11 fathers and 34 females with up to 3 children. All together 75 children without health problems are monitored.

• MeSH
• adjuvantní radioterapie MeSH
• bleomycin terapeutické užití   MeSH
• časové faktory MeSH
• cyklofosfamid terapeutické užití   MeSH
• dakarbazin terapeutické užití   MeSH
• dítě MeSH
• dospělí MeSH
• doxorubicin terapeutické užití   MeSH
• fertilita * MeSH
• Hodgkinova nemoc farmakoterapie   mortalita   patologie   MeSH
• kombinovaná terapie MeSH
• lidé středního věku MeSH
• lidé MeSH
• míra přežití MeSH
• novorozenec MeSH
• prednison terapeutické užití   MeSH
• přežívající MeSH
• příčina smrti MeSH
• prognóza MeSH
• prokarbazin terapeutické užití   MeSH
• protokoly antitumorózní kombinované chemoterapie terapeutické užití   MeSH
• rizikové faktory MeSH
• senioři MeSH
• staging nádorů MeSH
• vinblastin terapeutické užití   MeSH
• vinkristin terapeutické užití   MeSH
• výsledek terapie MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• bleomycin MeSH
• cyklofosfamid MeSH
• dakarbazin MeSH
• doxorubicin MeSH
• prednison MeSH
• prokarbazin MeSH
• vinblastin MeSH
• vinkristin MeSH

BACKGROUND: This authors team has been dealing with the Hodgkin disease problems since 1971. The MORHO study started at eight working places in 1978 according to unified diagnostic and medical protocol. The aim of this study is evaluation of influence of Hodgkin disease therapy on the fertility in young patients. PATIENTS AND METHODS: Group of patients treated for Hodgkin disease in years 1971-1996 at workplaces using the same treatment protocol has been analyzed and the results have been compared with results of other medical centers in the world. Some of the young patients in fertile age became parents after the treatment. RESULTS: Information of number of pregnancies and of children born, long term surveillance and complications of treatment has been collected and discussed. Many patients stayed fertile also after therapy of numerous relapses. There was 75 children born to 34 women and 11 men previously treated for Hodgkin disease. CONCLUSION: The results of our study are comparable with results of statistial evaluation of similar studies in the world cancer research centers.

• MeSH
• fertilita * MeSH
• Hodgkinova nemoc terapie   MeSH
• kombinovaná terapie MeSH
• lidé MeSH
• následné studie MeSH
• těhotenství MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH

BACKGROUND: This authors team has been dealing with the Hodgkin disease problems since 1971. The MORHO study started at eight working places in 1978 according to unified diagnostic and medical protocol. PATIENTS AND METHODS: 370 patients were treated. The treatment consisted in the combination of radiation and chemotherapy COPP and since 1988 in alternance of COPP and ABVD. Therapy was modificated with accordance to clinical stages and patient's histological type and age. Treatment of the patients over 50 was reduced in decades of one chemotherapy cycle less. RESULTS: Results from the clinical study are--patients with the stage IIA, IIB and IIIA survive 30 years in 59.29%, 57.86% and 60.72%. Patients diagnosed as stage IIIB survive after 30 years 36.78%, while patients in stages IVA and IVB survived 10 years 24.51% and 23.32% and 20 years 8.61% in stage IVB. Women survived longer than men. Histological types had no influence to the lenght of survival. The total number of relapses in the group was 55. There were 39 men and 16 women from that. 64% was in stage III and IV and in 73% mediastinal nodules were affected. 42% of relapses was till 1 year after the treatment. After the treatment 75 children were born to the patients from the group. 60 children from that were born to the women under treatment. CONCLUSION: The success of therapy of Hodgkin's disease according to protocol created by expert group of study MORHO is comparable with results of similar studies in the world. The most important contribution of this study was unification of treatment protocol in Czechoslovakia. This study changed the formerly paliative therapy to real curative treatment.

• MeSH
• Hodgkinova nemoc mortalita   patologie   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• míra přežití MeSH
• následné studie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Geografické názvy
• Česká republika epidemiologie   MeSH

BACKGROUND: On the 25th anniversary of the unified protocol of 1978, the authors report the results of the first clinical study in the Czech Republic performed in patients with Hodgkin's lymphoma. 290 patients were treated with both chemotherapy (Cyklophosphamide, Natulan, Prednison, Vinblastin) and radiotherapy according to this widely used protocol. The dosage of cytotoxic therapy was reduced based on age, in patients over 50 years of age. METHODS AND RESULTS: In the year 2003, the survival rate was 77.3% (194/290 patients) and of these, 85% (165/194 patients) have lived more than 10 years with complete remission. Of the 194 surviving patients, 24 were successfully treated for relapses. Of the 66 (22.8%) patients that died, the cause of death in 33 patients was Hodgkin's lymphoma. 33 women of the studied group gave birth to 43 children. In one case, phocomelia was diagnosed post-partum. In this instance, no causal relationship to the cytotoxic treatment (which had been given three years before the birth) could be established. The second child of the same mother was born healthy. In one case, a possible genetic relationship was noted--both the father and the daughter suffered from Hodgkin lymphoma and the granddaughter from non-Hodgkin lymphoma. CONCLUSIONS: The success of this treatment depends on complex diagnostic procedures, and on an experienced team of physicians.

• MeSH
• dospělí MeSH
• Hodgkinova nemoc mortalita   terapie   MeSH
• indukce remise MeSH
• lidé středního věku MeSH
• lidé MeSH
• míra přežití MeSH
• následné studie MeSH
• recidiva MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH

From a group of 366 patients with complete data complete remission was achieved by 290. Fifty-five patients relapsed, 39 men and 16 women, mostly with an initial finding of advanced disease (KS III + IV 64%), with affection of the mediastinum (73%) aged under 40 years. 42% of the relapses were detected within one year after termination of primary treatment and 33% during the subsequent 2 years, the longest interval before a relapse being 20 years. During primary treatment in 63% of the patients chemotherapy was reduced to 75-25% of the total dose of cytostatics with protraction of the interval between cycles in 58% and radiotherapy in another 34% of the patients. 76% of the patients with a first relapse achieved a second complete remission and 29 of them survive without signs of the disease, 12 died from generalized lymphoma. Sixteen patients developed repeated relapses (nine two relapses, four three relapses, another two four relapses and one patient five relapses). After treatment of the relapse a total of 22 patients died, incl. 19 who died from Hodgkin's disease, two from secondary carcinoma and one from myocardial infarction. The longest survival period after treatment of a relapse was 26 years.

• MeSH
• dospělí MeSH
• Hodgkinova nemoc patologie   terapie   MeSH
• lidé MeSH
• recidiva MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH

Pulmonary ventilation was monitored in a group of 102 patients with Hodgkin's disease. In the initial finding a tendency of a restrictive disorder is apparent (43% of the patients) with the increasing size of the mediastinal tumour (79% mediastinal patients with a bulky finding in 40%), without statistical significance. After treatment a restrictive disorder was recorded in 35% of the patients with a normal initial finding and conversely normalization of results occurred in 12% patients with a pathological result of the spirometric examination. After a one-year interval the finding deteriorated in 12 % of the patients without post-treatment disorders of pulmonary ventilation and in 15% the assessed disorder receded. Statistical analysis did not reveal a significant relationship between the results of spirometry and bleomycin treatment. 77 patients were examined after an interval of 2, 3, 4 and more years following termination of primary treatment without a significant correlation of the development of the a restrictive disorder and bleomycin administration. Pulmonary ventilation after treatment was examined in a total of 228 patients with the finding of restrictive changes in 94 (41%). Pulmonary fibrosis was diagnosed in 21 patients (9%) with a rising incidence two years after terminated treatment.

• MeSH
• dospělí MeSH
• Hodgkinova nemoc terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mechanika dýchání * MeSH
• nádory mediastina terapie   MeSH
• plicní fibróza etiologie   MeSH
• plicní nemoci diagnóza   etiologie   prevence a kontrola   MeSH
• spirometrie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• práce podpořená grantem MeSH

The impact of prognostic factors for survival was analyzed in a group of 337 patients with Hodgkin's disease. The analysis of survival of patients comprised a total of 13 indicators: histological types LP, NS, MC, LD, clinical stages I, II, III, IV, E lesions, symptomatology A, B, size of the mediastinal tumour (index), age at onset of disease and sex. Cumulative survival of 5, 10, and 20 years in the whole group is 83%, 80% and 72% resp. A first complete remission was achieved by 284 patients, cumulative survival without the disease is 79% after 5 and 73% after 10 years since completion of primary treatment. A significantly adverse effect on the prognosis of survival is exerted by symptomatology B, a large mediastinal tumour, advanced age, clinical stage IV and III. Most important are the first two factors mentioned. An adverse prognostic factor for survival without disease is male sex. The therapeutic protocol was repeatedly modified in the course of 25 years with regard to prognostic patient groups.

• MeSH
• dospělí MeSH
• Hodgkinova nemoc mortalita   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lymfatické metastázy MeSH
• mediastinum MeSH
• míra přežití MeSH
• prognóza MeSH
• rizikové faktory MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• práce podpořená grantem MeSH

The authors describe data on the course of pregnancy, delivery and subsequent development of 20 children born to parents treated for Hodgkin's disease. Thirteen women in the clinical stage II and III were delivered of 16 infants (10 daughters and 6 sons) and three men (II A and III A) had four daughters. The parents were in one case treated by irradiation only, twice by chemotherapy only and thirteen times by a combination of irradiation and chemotherapy (COPP/ABVD). The gestation period, parameters of the infants at delivery and the subsequent physical and mental development are normal. In one instance (a girl, now ten and a half years old) the child was born with malformations of the extremities; according to the geneticist this is not related to the previous treatment of the mother. The second child (a son) of this mother is normal. The authors are of the opinion and apply it in the therapeutic protocol in patients of fertile age and do not irradiate nodes in the pelvic region. In treated patients they allow pregnancy only after three or preferably five years following terminated treatment. Survival of patients in the whole group (269 subjects) regardless of age and clinical stage is 75%. The authors are processing a data base of Hodgkin patients since 1968.

• MeSH
• antitumorózní látky škodlivé účinky   MeSH
• dítě MeSH
• dospělí MeSH
• Hodgkinova nemoc terapie   MeSH
• kojenec MeSH
• lidé MeSH
• následné studie MeSH
• novorozenec MeSH
• pánev účinky záření   MeSH
• předškolní dítě MeSH
• radioterapie škodlivé účinky   MeSH
• těhotenství MeSH
• vrozené vady etiologie   MeSH
• výsledek těhotenství MeSH
• vývoj dítěte * MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• kojenec MeSH
• lidé MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• antitumorózní látky MeSH

• MeSH
• dějiny 20. století MeSH
• krevní transfuze dějiny   MeSH
• lidé MeSH
• Check Tag
• dějiny 20. století MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• historické články MeSH
• Geografické názvy
• Československo MeSH

• MeSH
• hemostatika terapeutické užití   MeSH
• inbrední kmeny potkanů MeSH
• krvácení farmakoterapie   MeSH
• krysa rodu Rattus MeSH
• kyseliny uronové terapeutické užití   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• hemostatika MeSH
• kyseliny uronové MeSH
• traumacel MeSH Prohlížeč